The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial

Table 3 Comparing the sensory nerve conduction measurements between the two study groups

	n-3 PUFAs (Mean ± SD)	Placebo (Mean ± SD)	Mean Difference	95 % CI P-value
Sural nerve
aSAP1(μV)	9.95 (5.52–16.40)	5.50 (3.40–14.10)	--	.033***
aSAP 2^a	6.30 (4.60–10.30)	.00 (.00–7.32)		.052^b
%Change^c	− 36.68	− 100.00
SCV1(m/s)	43.99 ± 15.17	44.82 ± 6.27	−.83	−6.44 to 4.78, .766*
SCV 2	42.29 ± 15.51	29.67 ± 13.01	12.24	2.22 to 22.26, .018**
% Change	−3.84	− 33.80
Ulnar nerve
aSAP1(μV)	27.90 (16.82–42.77)	17.50 (12.40–35.50)	--	.144***
a- SAP 2	22.80 (6.20–27.30)	10.14 (2.70–18.60)		.430^b
% Change	− 18.28	− 42.06
SCV1(m/s)	51.66 ± 8.34	50.15 ± 8.23	1.50	−2.51 to 5.52, .457*
SCV 2	44.08 ± 11.14	42.62 ± 7.26	.98	−4.61 to 6.57, .726**
% Change	− 14.66	− 15.01

a-SAP sensory action potential amplitude, SCV sensory conduction velocity
*P value is reported based on Independent-Samples T-Test
**P value is reported based on the analysis of covariance, adjusted for baseline values
***P value is reported based on the Mann–Whitney U Test
^aOne month after the cessation of chemotherapy
^b P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
^cPercent change in proportion to the baseline values

ISSN: 2050-7771